PF-610355

PF-610355

Systematic (IUPAC) name
N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2-{[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide
Clinical data
Legal status	Development terminated
Routes of administration	Inhalation
Identifiers
CAS Number	862541-45-5
ATC code	None
PubChem	CID: 11505444
ChemSpider	9680243 Y
UNII	ZH5SMU97AJ Y
ChEMBL	CHEMBL1240967 Y
Chemical data
Formula	C34H39N3O6S
Molecular mass	617.76 g·mol−1

PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable ultra-long-acting β₂ adrenoreceptor agonist (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer. It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically-mediated adverse events. Its in vivo duration on action confirmed its potential for once-daily use in humans.

The investigation and development of PF-610355 were discontinued in 2011, likely for strategic and regulatory reasons.